VIR: Vir Biotechnology, Inc.
About
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Current Value
$6.861 Year Return
Current Value
$6.861 Year Return
Key Details
Market Cap
$954.40M
P/E Ratio
-1.77
1Y Stock Return
-26.51%
1Y Revenue Growth
-33.82%
Dividend Yield
0.00%
Price to Book
0.8
Strategies that include VIR
Stock's related to VIR
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PRLB | 51.89% | $907.12M | +1.96% | 0.00% |
| ADPT | 51.68% | $661.15M | +6.16% | 0.00% |
| CRSP | 50.97% | $4.01B | -30.49% | 0.00% |
| SEM | 48.88% | $4.79B | +59.80% | 1.35% |
| TILE | 48.60% | $1.45B | +150.00% | 0.16% |
| WAT | 46.87% | $20.47B | +25.51% | 0.00% |
| CLFD | 45.88% | $398.66M | +4.48% | 0.00% |
| TECH | 45.60% | $10.55B | +4.49% | 0.48% |
| LXRX | 45.38% | $318.44M | -18.44% | 0.00% |
| NTLA | 45.33% | $1.44B | -50.35% | 0.00% |
| RXRX | 45.17% | $1.80B | -4.13% | 0.00% |
| LMAT | 44.63% | $2.33B | +94.89% | 0.46% |
| DDD | 44.53% | $402.06M | -35.13% | 0.00% |
| SRI | 44.27% | $166.13M | -63.46% | 0.00% |
| ALEC | 44.18% | $377.04M | -19.46% | 0.00% |
| PGEN | 44.10% | $228.91M | -28.00% | 0.00% |
| EDIT | 43.97% | $204.72M | -75.49% | 0.00% |
| CSV | 43.88% | $590.66M | +75.49% | 1.16% |
| MITT | 43.82% | $199.19M | +31.07% | 9.79% |
| EXPO | 43.80% | $4.82B | +20.93% | 1.16% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NOC | 0.21% | $71.54B | +4.23% | 1.60% |
| TPST | 0.23% | $37.75M | -77.59% | 0.00% |
| GHI | -0.24% | $272.26M | -27.60% | 12.75% |
| ALL | 0.25% | $52.06B | +45.67% | 1.85% |
| TXO | -0.34% | $737.26M | -1.80% | 13.22% |
| MNR | -0.36% | $1.66B | -10.71% | 15.90% |
| PRT | 0.51% | $48.72M | -16.56% | 10.33% |
| AMBC | -0.59% | $584.50M | -17.09% | 0.00% |
| UUU | -0.72% | $4.97M | -41.89% | 0.00% |
| AJG | 0.72% | $64.17B | +17.51% | 0.80% |
| NAPA | 0.75% | $1.63B | +9.61% | 0.00% |
| CYCN | 0.83% | $4.77M | -16.19% | 0.00% |
| EDR | 0.84% | $9.01B | +19.26% | 0.82% |
| RSG | 0.86% | $66.05B | +31.79% | 1.04% |
| OXBR | -0.89% | $19.05M | +178.18% | 0.00% |
| DMLP | -0.90% | $1.58B | +18.00% | 10.54% |
| LITB | 0.90% | $35.48M | -75.45% | 0.00% |
| CBOE | 0.97% | $21.46B | +15.84% | 1.11% |
| MSDL | -1.18% | $1.83B | +0.66% | 7.26% |
| LICY | 1.18% | $53.41M | -60.56% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MCK | -15.06% | $78.15B | +35.51% | 0.42% |
| HUSA | -12.99% | $16.69M | -11.56% | 0.00% |
| ACGL | -8.57% | $36.00B | +16.84% | 0.00% |
| LMT | -8.13% | $126.40B | +18.99% | 2.36% |
| TCTM | -8.12% | $8.10M | -42.99% | 0.00% |
| PULM | -8.05% | $19.83M | +202.98% | 0.00% |
| AZO | -6.99% | $52.52B | +16.10% | 0.00% |
| TEM | -6.93% | $8.50B | 0.00% | 0.00% |
| CYD | -6.47% | $364.46M | -2.94% | 4.26% |
| MNOV | -6.45% | $93.19M | +2.15% | 0.00% |
| PGR | -6.42% | $149.10B | +57.29% | 0.45% |
| COR | -6.39% | $47.48B | +21.20% | 0.86% |
| ORLY | -6.32% | $69.31B | +22.06% | 0.00% |
| CME | -5.85% | $82.76B | +9.21% | 1.98% |
| BTCT | -5.53% | $42.61M | +353.33% | 0.00% |
| WM | -5.42% | $87.92B | +27.58% | 1.34% |
| STG | -5.31% | $35.67M | +7.92% | 0.00% |
| ERIE | -4.90% | $19.39B | +46.23% | 1.23% |
| LPTH | -3.97% | $62.27M | +33.05% | 0.00% |
| SRRK | -3.57% | $2.61B | +134.91% | 0.00% |
ETF's related to VIR
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| IBB | 59.23% | $6.66B | 0.45% |
| ARKG | 58.56% | $1.13B | 0.75% |
| GNOM | 57.47% | $70.59M | 0.5% |
| XBI | 56.50% | $6.58B | 0.35% |
| RSPA | 55.84% | $273.87M | 0% |
| FBT | 55.21% | $1.11B | 0.56% |
| IWC | 53.90% | $933.99M | 0.6% |
| PBE | 53.49% | $258.53M | 0.58% |
| BBH | 52.81% | $397.87M | 0.35% |
| DFAT | 52.10% | $11.16B | 0.28% |
| IWO | 51.31% | $12.56B | 0.24% |
| VTWO | 51.25% | $12.38B | 0.1% |
| IWM | 51.22% | $75.73B | 0.19% |
| PRNT | 50.47% | $95.35M | 0.66% |
| GSSC | 49.72% | $529.86M | 0.2% |
| PRFZ | 49.66% | $2.65B | 0.39% |
| IWN | 49.37% | $13.17B | 0.24% |
| VIOO | 49.30% | $3.12B | 0.1% |
| ESML | 49.28% | $1.90B | 0.17% |
| SMMD | 49.28% | $1.24B | 0.15% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| CLOI | 0.09% | $715.40M | 0.4% |
| SGOV | 0.11% | $27.53B | 0.09% |
| XHLF | 0.16% | $874.27M | 0.03% |
| CSHI | -0.17% | $482.85M | 0.38% |
| GBIL | -0.20% | $5.60B | 0.12% |
| DBO | 0.26% | $217.57M | 0.77% |
| HIGH | -0.34% | $302.78M | 0.51% |
| MINT | -0.42% | $11.62B | 0.35% |
| KRBN | 0.61% | $242.47M | 0.85% |
| DBE | 0.62% | $50.13M | 0.77% |
| FBY | 0.98% | $127.69M | 0.99% |
| SHV | 1.34% | $18.13B | 0.15% |
| CANE | -1.85% | $17.72M | 0.29% |
| COMT | 2.36% | $829.06M | 0.48% |
| BSCO | 2.37% | $2.35B | 0.1% |
| GSG | 2.37% | $914.42M | 0.75% |
| DBMF | 2.61% | $1.02B | 0.85% |
| BILZ | -2.63% | $563.02M | 0.14% |
| JUCY | 2.76% | $324.29M | 0.6% |
| TPMN | -2.78% | $40.60M | 0.65% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -38.81% | $388.04M | 1.43% |
| VIXY | -27.10% | $195.31M | 0.85% |
| USDU | -12.52% | $201.97M | 0.5% |
| TAIL | -12.26% | $67.98M | 0.59% |
| EQLS | -11.23% | $76.08M | 1% |
| UUP | -11.09% | $309.25M | 0.77% |
| CTA | -9.76% | $350.27M | 0.78% |
| AGZD | -9.23% | $142.76M | 0.23% |
| KMLM | -8.78% | $353.87M | 0.9% |
| KCCA | -8.66% | $220.51M | 0.87% |
| WEAT | -8.04% | $120.27M | 0.28% |
| HDRO | -6.54% | $164.26M | 0.3% |
| TBIL | -4.86% | $4.38B | 0.15% |
| DBA | -4.39% | $755.88M | 0.93% |
| XBIL | -4.23% | $637.70M | 0.15% |
| CORN | -3.89% | $61.12M | 0.2% |
| BOXX | -3.46% | $4.43B | 0.1949% |
| TPMN | -2.78% | $40.60M | 0.65% |
| BILZ | -2.63% | $563.02M | 0.14% |
| CANE | -1.85% | $17.72M | 0.29% |
News
Yahoo
SAN FRANCISCO, November 19, 2024--Vir Biotechnology, Inc. (NASDAQ:VIR) today announced positive results from the SOLSTICE Phase 2 clinical trial evaluating tobevibart alone, or in combination with elebsiran, in people with chronic hepatitis delta (CHD). The most-advanced and potential first-of-its-kind investigational human monoclonal antibody and siRNA combination dosed monthly achieved 100% virologic response and rapid hepatitis delta virus (HDV) RNA suppression. HDV RNA below the lower limit
Yahoo
SAN FRANCISCO, November 18, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has issued a positive opinion on the application for orphan drug designation of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD). This opinion is based on encouraging preliminary data from the Phase 2 SOLSTICE trial. Vir Biotechnology will present 24-week data from the Phase 2 SOLSTICE trial at
Finnhub
SAN FRANCISCO - Vir Biotechnology, Inc. today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart and elebsiran, with or without...
Yahoo
On Friday, Vir Biotechnology, Inc. (NASDAQ:VIR) announced end-of-treatment data from Part B of the MARCH Phase 2 study evaluating combinations of tobevibart and elebsiran, with or without pegylated interferon alfa (PEG-IFNα), in participants with chronic hepatitis B. Chronic hepatitis B (CHB) is a long-lasting, inflammatory liver disease caused by the hepatitis B virus (HBV). The World Health Organization estimates that 254 million people live with CHB, and an estimated 1.1 million yearly deaths
SeekingAlpha
VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. Find out why VIR stock is a Buy.
Yahoo
The analysts might have been a bit too bullish on Vir Biotechnology, Inc. ( NASDAQ:VIR ), given that the company fell...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.